sb-267268

Description: SB-267268 is a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity. SB-267268 reduced pathologic angiogenesis in ROP mice by approximately 50% and had no effect on developmental retinal angiogenesis in shams. Both VEGF and VEGFR-2 mRNA were upregulated in the inner retina of ROP mice and reduced with SB-267268. Nonpeptidic inhibition of alpha(v)beta3 and alpha(v)beta5 integrins is effective in ROP and may be a suitable anti-angiogenic therapy for other ischemic retinal pathologies.

References: Wilkinson-Berka JL, Jones D, Taylor G, Jaworski K, Kelly DJ, Ludbrook SB, Willette RN, Kumar S, Gilbert RE. SB-267268, a nonpeptidic antagonist ofalpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGFexpression in a mouse model of retinopathy of prematurity. Invest Ophthalmol VisSci. 2006 Apr; 47(4):1600-5. PubMed PMID: 16565398.